Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sin3A-associated protein 130 (SAP130) is a core subunit of the histone deacetylase-dependent SIN3A corepressor complex, where it acts as a scaffold and regulatory partner facilitating chromatin remodeling and transcriptional repression through histone and non-histone protein deacetylation. SAP130 binds both the SIN3A scaffold and HDAC1 enzyme within this multi-protein complex and helps stabilize its repressive functions on target genes. It plays a crucial role in epigenetic gene regulation, with evidence from animal models implicating it in heart development and demonstrating that its loss can cause severe developmental syndromes such as hypoplastic left heart syndrome. SAP130 is not a spliceosomal protein (in contrast to the similarly named SF3B3, which was formerly called "spliceosome-associated protein 130" and is a source of literature confusion). SAP130 itself is not a direct drug target or therapeutic biomarker and is considered essential for embryonic development and tissue homeostasis.
Not applicable; SAP130 is not directly targeted by drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sin3A-associated protein 130 (SAP130).